Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PMGC Holdings ( (ELAB) ) just unveiled an announcement.
On February 11, 2026, Northstrive Biosciences, a subsidiary of PMGC Holdings, announced it had signed a definitive, exclusive worldwide license agreement with Modulant Biosciences for EL-22 and EL-32 in non-human animal health, excluding South Korea. The deal grants Modulant rights to develop, manufacture, and commercialize myostatin- and activin-A–engineered probiotic products, including as feed additives, while excluding any human pharmaceutical uses.
Under the agreement, Modulant assumes responsibility for development, manufacturing, regulatory, and commercialization efforts, with provisions for sublicensing, shared ownership of improvements, and adherence to industry regulatory and quality standards. The transition from a 2025 term sheet to a fully executed license marks a key milestone for Northstrive, aiming to translate its muscle-preserving technologies into animal health applications and potentially enhance PMGC’s positioning in the growing global animal health and nutrition market.
The most recent analyst rating on (ELAB) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on PMGC Holdings stock, see the ELAB Stock Forecast page.
Spark’s Take on ELAB Stock
According to Spark, TipRanks’ AI Analyst, ELAB is a Neutral.
The score is held down primarily by weak financial fundamentals (ongoing losses and significant cash burn) and strongly bearish technical momentum (price well below major moving averages with oversold indicators). A positive pipeline-related corporate update provides some support, but valuation is not meaningfully assessable from the provided P/E and dividend data.
To see Spark’s full report on ELAB stock, click here.
More about PMGC Holdings
PMGC Holdings Inc. is a diversified holding company that grows a portfolio of businesses through strategic acquisitions, investments, and development across multiple industries. Its subsidiary Northstrive Biosciences operates as a biopharmaceutical firm focused on cutting-edge aesthetic medicines, with lead asset EL-22 using an engineered probiotic approach to help preserve muscle during obesity and GLP-1-based weight-loss treatments.
Northstrive’s work centers on myostatin- and activin-A–targeting technologies that regulate muscle development, strength, and metabolic efficiency, positioning the business at the intersection of metabolic health, muscle preservation, and advanced biologics. PMGC targets value creation by backing such specialized platforms while Modulant Biosciences, a veterinary-focused biotechnology company, advances novel drugs and biologics for livestock, companion, and aquatic animals.
Average Trading Volume: 523,790
Technical Sentiment Signal: Sell
Current Market Cap: $1.99M
Learn more about ELAB stock on TipRanks’ Stock Analysis page.